Shop

Showing 1073–1088 of 1319 results

Article: RAS-testing in colorectal cancer: Belgian guidelines
€3.03 Add to cart
Article: Reactivations of prior infections in cancer patients treated with immunosuppressive/immunomodulatory treatments
€3.03 Add to cart
Article: Real life cost of treatment and follow-up of patients with glioblastoma in Belgium: a retrospective patient chart review
€3.03 Add to cart
Article: Real-life outcome of optimally treated patients with malignant glioma
€3.03 Add to cart
Article: Real-life value of follow-up FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemoradiation (CRT) or (chemo)radiation ([C]RT) preceded by induction chemotherapy (IC) (sequential treatment [ST]).
€3.03 Add to cart
Article: Real-world evidence for implementation of new drugs
€3.03 Add to cart
Article: Real-world evidence with durvalumab after chemoradiotherapy in patients with unresectable NSCLC
€3.03 Add to cart
Article: Real-world treatment practices for EGFR-mutant NSCLC patients
€3.03 Add to cart
Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’
€3.03 Add to cart
Article: Rebuttal to “The role of direct oral anticoagulants in the management of cancer-associated thrombosis’
€3.03 Add to cart
Article: Recent advances in small-cell lung cancer treatment
€3.03 Add to cart
Article: Recurrent and metastatic non-nasopharyngeal head and neck cancer: state of the art of systemic treatment
€3.03 Add to cart
Article: Reflex testing for mutations in patients with early-stage non-small cell lung cancer: practical implications from ADAURA
€3.03 Add to cart
Article: Refractory pyrexia caused by BRAF and MEK inhibitors: Colchicine as salvage
€3.03 Add to cart
Article: Relationship between volume and outcome in lung cancer
€3.03 Add to cart
Article: Renal cell carcinoma
€3.03 Add to cart

Article: RAS-testing in colorectal cancer: Belgian guidelines

Article: Reactivations of prior infections in cancer patients treated with immunosuppressive/immunomodulatory treatments

Article: Real life cost of treatment and follow-up of patients with glioblastoma in Belgium: a retrospective patient chart review

Article: Real-life outcome of optimally treated patients with malignant glioma

Article: Real-life value of follow-up FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemoradiation (CRT) or (chemo)radiation ([C]RT) preceded by induction chemotherapy (IC) (sequential treatment [ST]).

Article: Real-world evidence for implementation of new drugs

Article: Real-world evidence with durvalumab after chemoradiotherapy in patients with unresectable NSCLC

Article: Real-world treatment practices for EGFR-mutant NSCLC patients

Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’

Article: Rebuttal to “The role of direct oral anticoagulants in the management of cancer-associated thrombosis’

Article: Recent advances in small-cell lung cancer treatment

Article: Recurrent and metastatic non-nasopharyngeal head and neck cancer: state of the art of systemic treatment

Article: Reflex testing for mutations in patients with early-stage non-small cell lung cancer: practical implications from ADAURA

Article: Refractory pyrexia caused by BRAF and MEK inhibitors: Colchicine as salvage

Article: Relationship between volume and outcome in lung cancer

Article: Renal cell carcinoma